< < < < < NeuromicsAntibodes.de powered by Acris Antibodies > > >    < < < Here are the antibodies you are looking for > > > > >

Neuromics Antibodiespowered by Acris Antibodies

 

Acris Antibodies

 

 

 

Neuromics Inc.

 

 

Antibody to Leukemia Inhibitory Factor (LIF)

 

Catalog Number:

GT15069

 

Product Type:

Affinity purified

Immunogen Sequence:

Recombinant mouse leukemia inhibitory factor (LIF)

 

Host:

Goat

 

Reactivity:

Mouse, Rat

 

Applications:

Immunohistochemistry on paraffin sections, ELISA, Western Blot

GT15069

Immunohistochemical staining of LIF in rat peripheral nerve. LIF-immunoreactivity is shown in red and Haematoxylin counterstain in blue.

 

Description:

This factor is produced by various fibroblast cell lines, antigen-stimulated alloreactive T-lymphocytes, mitogen-activated spleen cells, and Krebs and Ehrlich ascites cells. The factor is produced also by monocytes after cell activation . Human lung fibroblasts and umbilical chord endothelial cells produce LIF constitutively. The synthesis in mesenchymal cells of LIF can be induced by IL1-alpha, TGF-beta , EGF , and bFGF LIF is a heavily and variably glycosylated 58 kDa protein. with a length of 179 amino acids. Glycosylation does not appear to be essential for bioactivity. LIF was isolated initially as a factor that inhibits many, but not all, myeloid leukemia cells and induces their differentiation into macrophages. For some myeloid leukemia cell lines such as M1 a short pulse of LIF is sufficient to initiate irreversible differentiation. Cultured normal human bone marrow stromal cells constitutively express LIF message. Exposure of these cells to IL1 , TGF-beta , and TNF-alpha (but not IFN-alpha ) increases the level of LIF mRNA. Cultured stromal cells derived from patients with chronic myelogenous leukemia show enhanced LIF expression. LIF may participate, either alone or through interaction with other cytokines , in the bone marrow microenvironment mediated influence on both normal and malignant hematopoietic processes. LIF has been shown to be a potent inhibitor of endothelial cell proliferation. LIF is a factor that inhibits adipogenesis by inhibiting the lipoprotein lipase in adipocytes. The inhibition of this enzyme probably reduces uptake of fatty acids by adipocytes and leads to catabolism of lipids in fat tissue. Mice with a high blood level of LIF suffer from weight loss and are also cachectic. In addition one also observes an accumulation of osteoblasts in the bone marrow and formation of new bone tissues and calcifications in the heart and skeletal muscles. A marked increase in the number of hematopoietic cells is found in spleen and liver. In mice injected with LIF megakaryocyte and platelet counts rise.

 

Reference:

Gearing DP Leukaemia inhibitory factor: does the cap fit? Annals of the New York Academy of Sciences 628: 9-18 (1991)

 

Gough NM and Williams RL The pleiotropic actions of leukaemia inhibitory factor. Cancer Cells 1: 77-80 (1989)

 

Hilton DJ and Gough NM Leukemia inhibitory factor: A biological perspective. Journal of Cellular Biochemistry 46: 21-6 (1991)

 

Hilton DJ LIF: lots of interesting functions Trends in Biochemical Sciences 17: 72-6 (1992)

 

Kurzrock R et al LIF: not just a leukaemia inhibitory factor. Endocrinol. Rev. 12: 208-17 (1991)

 

Metcalf D The leukaemia inhibitory factor (LIF). International Journal of Cell Cloning 9: 95-108 (1991)

 

Metcalf D Leukemia inhibitory factor - a puzzling polyfunctional regulator. Growth Factors 7: 169-73 (1992)

 

 

Datasheet download

 

 

 

© 2004-2010 Acris Antibodies   -   All rights reserved   -   Imprint